Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)

Conditions

• PASC Post Acute Sequelae of COVID-19

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Accepted

Interventions

• A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static) — DRUG
  Participants receive an intravenous injection of 5 mCi (±20%) of \[¹⁸F\]F-AraG followed by a 90-minute total-body PET/CT scan and an additional 30-minute static scan at 4 hours post-injection. Blood samples (up to 42 mL total) are collected during dynamic imaging.
• A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only) — DRUG
  Participants receive an intravenous injection of 5 mCi (±20%) of \[¹⁸F\]F-AraG followed by a 60-minute total-body PET/CT scan. Blood samples (up to 42 mL total) are collected during dynamic imaging.
• B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static) — DRUG
  Participants receive an intravenous injection of 5 mCi (±20%) of \[¹⁸F\]F-AraG followed by a 90-minute total-body PET/CT scan and a second 30-minute scan at 4 hours. Blood samples (up to 42 mL total) are collected during dynamic imaging.
• B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only) — DRUG
  Participants receive 5 mCi (±20%) of \[¹⁸F\]F-AraG intravenously followed by a 60-minute total-body PET/CT scan. Blood samples (up to 42 mL total) are collected during dynamic imaging.

Study Details

This study uses total-body \[¹⁸F\]F-AraG PET/CT imaging to investigate immune activation and vascular changes in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Participants will undergo dynamic PET/CT imaging along with blood biomarker assessments and symptom evaluations. The study aims to characterize sites of immunological perturbation, correlate PET imaging findings with peripheral blood markers, and evaluate longitudinal changes in tissue-based immune activity in relation to symptom patterns over time. Data from this study will improve understanding of tissue-level immune dysregulation in PASC and support future clinical tools for assessing and managing this condition.

Key Dates

Start date

Dec 4, 2025

Status verified

May 2026

Primary completion

Dec 31, 2028

Completion

Dec 31, 2029

Study Design

Enrollment

51 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Arms

• Experimental: A.1 - Control Group (90-min dynamic + 4-h static PET/CT)
  Control participants in this arm will undergo a 90-minute dynamic \[¹⁸F\]F-AraG total-body PET/CT scan, followed by a second 30-minute static PET/CT scan approximately 4 hours after tracer injection. Blood samples will be collected during the dynamic scan to support kinetic modeling.
• Experimental: A.2 - Control Group (60-min dynamic PET/CT only)
  Control participants in this arm will undergo a 60-minute dynamic \[¹⁸F\]F-AraG total-body PET/CT scan. No delayed imaging will be performed. Blood samples will be collected during the dynamic scan.
• Experimental: B.1 - PASC Group (90-min dynamic + 4-h static PET/CT)
  PASC participants in this arm will undergo a 90-minute dynamic \[¹⁸F\]F-AraG total-body PET/CT scan, followed by a second 30-minute static scan approximately 4 hours post-injection. Blood samples are collected during the scan.
• Experimental: B.2 - PASC Group (60-min dynamic PET/CT only)
  PASC participants in this arm will undergo a 60-minute dynamic \[¹⁸F\]F-AraG PET/CT scan. No delayed imaging is performed. Blood samples are collected during imaging.

Primary Outcome Measure

Quantification of [¹⁸F]F-AraG uptake kinetics in PASC and control participants [ Time Frame: Baseline Imaging Visit ]

Central Contacts

• Clinical Research Team
  415-502-2449
  [email protected]
• Lynn Ngo
  [email protected]

Locations (2)

Find similar trials in Sacramento, CA

Related Studies

• Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection
  Recruiting · National Institute of Neurological Disorders and Stroke (NINDS) · Bethesda, Maryland